Literature DB >> 12846061

Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis.

T Yamamoto1.   

Abstract

Scleroderma is a connective tissue disease of unknown etiology characterized by the excessive deposition of extracellular matrix in the skin. Cellular infiltrates of certain immune cells and pro-inflammatory mediators are suggested to play a crucial role in cutaneous fibrosis, forming complicated networks between fibroblasts and immune cells and/or cell-cell communications. Tissue-selective trafficking of leukocytes is mediated by combinations of adhesion molecules and chemokines. Although chemokines and their receptors are considered to be mediators of inflammation and fibrosis in scleroderma, their pathophysiological role remains incompletely understood. Recent studies suggest that CCL2/monocyte chemoattractant protein-1 plays an important role in the fibrotic process, including liver fibrosis, pulmonary fibrosis, and scleroderma. This review summarizes recent findings of the potential roles of CCL2 in cutaneous sclerosis in experimental animal models of scleroderma as well as human scleroderma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846061

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

2.  Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells.

Authors:  Jing Huang; Lori L Stohl; Xi Zhou; Wanhong Ding; Richard D Granstein
Journal:  Brain Behav Immun       Date:  2011-02-18       Impact factor: 7.217

3.  MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-an Wang; Christopher Fuller; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.